Bremner Fion
Department of Neuro-Ophthalmology, National Hospital for Neurology and Neurosurgery, London, United Kingdom.
Front Neurol. 2019 Jan 31;10:55. doi: 10.3389/fneur.2019.00055. eCollection 2019.
In suspected cases of Horner syndrome pharmacological confirmation is often required before embarking on further investigations. There are two drugs currently used for this purpose that are commercially available for topical administration: cocaine (2-10%) and apraclonidine (0.5-1.0%). To evaluate and compare the effects of both drugs in normal eyes and eyes with Horner syndrome This is a retrospective study looking at the outcome of 660 consecutive pharmacological tests with these two drugs in one tertiary referral center over 14 years. Eyes were categorized as "normal" or "Horner syndrome" based on criteria (pupillometric and clinical evidence). Pupil diameters in the dark and in bright light were measured by pupillometry before and 40 min after administration of the test drug (either 4% cocaine or 0.5% apraclonidine). Cocaine dilated the normal pupil (measured in bright light: mean +2.1 mm, range -0.4 to +3.9 mm; 95% lower limit +0.5 mm); the extent of this response was not significantly affected by patient age or pupil size, but was 50% less in brown eyes compared with blue or green eyes, and 20% less if the measurements were made in the dark. In eyes with Horner syndrome cocaine had significantly less mydriatic effect (mean +0.7 mm, range -0.7 to +2.9 mm). Apraclonidine constricted the normal pupil (measured in the dark: mean -0.4 mm, range -1.3 to +0.8 mm; 95% upper limit +0.1 mm); eye color made no difference but the response was significantly greater in younger patients and larger pupils and significantly less if measured in bright lighting conditions. In eyes with Horner syndrome apraclonidine dilated the pupil (mean +0.6, range -0.4 to +2.3 mm). Applying the 95% limits identified from my normative data, I estimate the sensitivity of each drug test for detection of Horner syndrome at 40% for cocaine (criterion for abnormal: mydriasis ≤0.5 mm when measured in the dark) compared with 93% for apraclonidine (criterion for abnormal: mydriasis ≥0.1 mm when measured in the dark). Apraclonidine is a more sensitive test than cocaine for detection of Horner syndrome, and should be adopted as the new gold standard in routine clinical practice. However, caution is needed when using this drug within hours of a suspected sympathetic lesion, or in infants under 1 year of age.
在疑似霍纳综合征的病例中,通常需要进行药物确认后才能开展进一步检查。目前有两种用于此目的且可通过商业途径获得的局部用药:可卡因(2 - 10%)和阿可乐定(0.5 - 1.0%)。为评估和比较这两种药物对正常眼睛和霍纳综合征患者眼睛的影响,这是一项回顾性研究,观察了在一个三级转诊中心14年间连续使用这两种药物进行的660次药理学测试的结果。根据标准(瞳孔测量和临床证据)将眼睛分为“正常”或“霍纳综合征”。在给予测试药物(4%可卡因或0.5%阿可乐定)之前及之后40分钟,通过瞳孔测量法测量暗光和亮光下的瞳孔直径。可卡因使正常瞳孔扩大(在亮光下测量:平均增加2.1毫米,范围为 - 0.4至 + 3.9毫米;95%下限为 + 0.5毫米);这种反应的程度不受患者年龄或瞳孔大小的显著影响,但与蓝色或绿色眼睛相比,棕色眼睛的反应减少50%,且在暗光下测量时减少20%。在霍纳综合征患者的眼睛中,可卡因的散瞳作用明显较小(平均增加0.7毫米,范围为 - 0.7至 + 2.9毫米)。阿可乐定使正常瞳孔缩小(在暗光下测量:平均减少0.4毫米,范围为 - 1.3至 + 0.8毫米;95%上限为 + 0.1毫米);眼睛颜色无差异,但年轻患者和较大瞳孔的反应明显更大,且在明亮光照条件下测量时明显更小。在霍纳综合征患者的眼睛中,阿可乐定使瞳孔扩大(平均增加0.6,范围为 - 0.4至 + 2.3毫米)。根据我的正常数据确定的95%界限,我估计可卡因检测霍纳综合征的每种药物测试的敏感性为40%(异常标准:在暗光下测量时瞳孔散大≤0.5毫米),而阿可乐定的敏感性为93%(异常标准:在暗光下测量时瞳孔散大≥0.1毫米)。对于检测霍纳综合征,阿可乐定是比可卡因更敏感的测试,应在常规临床实践中作为新的金标准采用。然而,在疑似交感神经损伤后数小时内或1岁以下婴儿使用此药物时需要谨慎。